Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Bullous/Blistering Skin Disorders
Should nivolumab be discontinued in a patient who develops bullous pemphigoid but is otherwise responding well to therapy, if BP is being managed with dupilumab?
Related Questions
How do you manage pemphigus vulgaris in patients who lack insurance coverage for biologics and routine laboratory monitoring?
Are there patients with pemphigus whom you plan to give additional doses of rituximab even if they are in complete remission at six months from their initial dose?
How do you approach postoperative radiation therapy in a patient with head and neck cancer who has high risk of recurrence in the setting of active epidermolysis bullosa?
Does the presence of paraneoplastic pemphigus influence your treatment options in CLL?
What treatment combination approach would you recommend for mucous membrane pemphigoid?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
How do you manage pemphigus patients who have persistent disease and circulating autoantibodies despite two full courses of rituximab?
How have you used Hedgehog pathway inhibitors as neoadjuvant/adjuvant therapies?
How do you counsel patients with chronic urticaria on the role of stress management strategies in their treatment plan?
Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?
